Abstract
A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public–private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps
The Journal of Antibiotics Open Access 01 November 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations http://amr-review.org (2016).
Laxminarayan, R. et al. Antibiotic resistance—the need for global solutions. Lancet Infect. Dis. 13, 1057–1098 (2013).
Rex, J. H. & Outterson, K. Antibiotic reimbursement in a sales-delinked model: context and a benchmark-based global approach. Lancet Infect. Dis. 16, 500–505 (2016).
Outterson, K. New business models for sustainable antibiotics. Chatham House http://www.chathamhouse.org/publications/papers/view/197446 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.H.R. is an employee and shareholder of AstraZeneca Pharmaceuticals, non-executive board member, senior advisor and shareholder of F2G Pharmaceuticals; non-executive board member of Adenium Biotech ApS; Expert-in-residence, Wellcome Trust; and operating partner and consultant, Advent Life Sciences. P.J. is executive director of AMR Centre Ltd; non-executive director of Redx Pharma Plc; non-executive director of Yprotech Ltd; non-executive director of Biovictrix Therapeutics Ltd; and owner and director of Intelia Consulting.
Related links
Rights and permissions
About this article
Cite this article
Outterson, K., Rex, J., Jinks, T. et al. Accelerating global innovation to address antibacterial resistance: introducing CARB-X. Nat Rev Drug Discov 15, 589–590 (2016). https://doi.org/10.1038/nrd.2016.155
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.155
This article is cited by
-
Building Capacity in Infection Prevention and Antimicrobial Stewardship in Low- and Middle-Income Countries: the Role of Partnerships Inter-countries
Current Treatment Options in Infectious Diseases (2018)
-
Preclinical antibiotic pipeline gets a pick-me-up
Nature Reviews Drug Discovery (2017)
-
Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps
The Journal of Antibiotics (2017)